 ValuEngine downgraded shares of Flexion Therapeutics NASDAQ:FLXN from a buy rating to a hold rating in a research note released on Wednesday, ValuEngine reports. FLXN has been the topic of several other reports. Benchmark decreased their price target on shares of Flexion Therapeutics from 25.00 to 17.00 and set a buy rating on the stock ... 